Outcomes of patients with pathologic complete response following neoadjuvant HER2-targeted therapy in patients with HER2+early stage breast cancer

被引：0
|
作者：
O'Shaughnessy, Joyce
Oestreicher, Nina
Fulcher, Nicole
Tseng, Wan-Yu
Beeks, April
Moore, Julia
Lalla, Deepa
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P3-12-20
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-12-20
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Predictors of pathologic complete response in HER2 positive breast cancer patients treated with neoadjuvant targeted therapy
    Rosario, Mariela Huerta
    Sahoo, Sunati
    CANCER RESEARCH, 2020, 80 (04)
  • [2] Neoadjuvant Dual HER2-Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2-Positive Breast Cancer: A Meta-Analysis of Randomized Prospective Clinical Trials
    Hicks, Mellissa
    Macrae, Erin R.
    Abdel-Rasoul, Mahmoud
    Layman, Rachel
    Friedman, Susan
    Querry, Jenny
    Lustberg, Maryam
    Ramaswamy, Bhuvaneswari
    Mrozek, Ewa
    Shapiro, Charles
    Wesolowski, Robert
    ONCOLOGIST, 2015, 20 (04): : 337 - 343
  • [3] Serum Enzymes and Pathologic Complete Response to the Addition of Targeted Therapy in Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer Patients
    Chen, Zongshun
    Zhang, Jing
    Chen, Wei
    Chen, Xueyi
    Lu, Da-Lin
    Li, Junjie
    ANNALS OF SURGICAL ONCOLOGY, 2025, : 4008 - 4016
  • [4] HER2-Targeted Therapy for Early-Stage Breast Cancer: A Comprehensive Review
    Brown-Glaberman, Ursa
    Dayao, Zoneddy
    Royce, Melanie
    ONCOLOGY-NEW YORK, 2014, 28 (04): : 281 - 289
  • [5] Neoadjuvant Trastuzumab in HER2+early breast cancer patients - one clinic experience
    Petruzelka, L.
    Bielcikova, Z.
    Zimovjanova, M.
    Tesarova, P.
    Pribylova, J.
    Hejduk, K.
    Chloupkova, R.
    BREAST, 2017, 32 : S78 - S78
  • [6] HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials
    Dent, Susan
    Oyan, Basak
    Honig, Amd
    Mano, Max
    Howell, Sacha
    CANCER TREATMENT REVIEWS, 2013, 39 (06) : 622 - 631
  • [7] Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis
    Swain, Sandra M.
    Macharia, Harrison
    Cortes, Javier
    Dang, Chau
    Gianni, Luca
    Hurvitz, Sara A.
    Jackisch, Christian
    Schneeweiss, Andreas
    Slamon, Dennis
    Valagussa, Pinuccia
    du Toit, Yolande
    Heinzmann, Dominik
    Knott, Adam
    Song, Chunyan
    Cortazar, Patricia
    CANCERS, 2022, 14 (20)
  • [8] Investigating the immune profile of early stage HER2+breast cancer patients receiving chemotherapy and HER2-targeted therapies
    Collins, Denis M.
    Gaynor, Nicola
    Madden, Stephen
    Toomey, Sinead
    Qiu, Ji
    Blayney, Jaine
    Blanco, Alfonso
    Fletcher, Jean
    Moran, Barry
    Kaukonen, Damien
    Ramirez, Javier Sanchez
    Kay, Elaine
    O'Connor, Darran
    Teiserskiene, Ausra
    Eustace, Alex
    Kennedy, Richard
    LaBaer, Joshua
    Gallagher, William
    Hennessy, Bryan
    Crown, John
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 487 - 487
  • [9] A neutrophil to lymphocyte ratio is predictive of response to neoadjuvant HER2-targeted therapies in the patients with HER2-positive breast cancer.
    Bae, Soong June
    Yoon, Chang-Ik
    Park, So Eun
    Cha, Chi Hwan
    Kim, Dooreh
    Lee, Janghee
    Ahn, Sung Gwe
    Park, Hyung Seok
    Cho, Youngup
    Jeong, Joon
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Loss of HER2 after neoadjuvant treatment of HER2+early breast cancer
    Morales, S.
    Gasol Cudos, A.
    Rodriguez Galindo, A.
    Velasco, A.
    Canosa Morales, C.
    Sanchez Guzman, D. -R.
    Mele Olive, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S51 - S51
12345